


Schema



Treatment for Arm 1 patients will consist of temozolomide and olaparib for 13 cycles followed by continuation of olaparib alone as maintenance therapy or until disease progression, unacceptable adverse event, or withdrawal of consent. Treatment for Arm 2 patients will consist of temozolomide alone for 13 cycles or until disease progression, unacceptable adverse event, or withdrawal of consent. Patients will be followed for 5 years or until death, whichever comes first.

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

Treatment must be administered and imaging must be conducted at the registering institution.

If the Group credited for enrollment is a non-Alliance Group, then other requirements from the credited Group may apply.